DelSiTech
DelSiTech is a Finnish drug delivery technology company specializing in biodegradable silica-based controlled release of small molecule drugs, biopharmaceuticals, viral vectors, and complex biomolecules. The company focuses on parenteral and local administration of drug products, with a mission to develop innovative drug delivery solutions for high unmet clinical needs and to become a leading player in the supergeneric drug development segment. DelSiTech collaborates with global pharmaceutical and biotech companies, holds multiple patents, and actively advances its proprietary silica matrix technology through research, development, and strategic partnerships.
Industries
Nr. of Employees
small (1-50)
Patents
Method for storing silica-based material, package produced with the method and use of package for packaging of silica-based products
US-9226893-B2
View Details
Method for storing silica-based material, package produced with the method and use of package for packaging of silica-based products
US-9226893-B2
View DetailsProducts
DelSiTech Silica Matrix
A biodegradable silica-based drug delivery technology for controlled release of small molecules, biopharmaceuticals, and viral vectors.
DST1308
An injectable subcutaneous depot product for chronic hepatitis B, designed to improve patient adherence by providing a three-month release of the antiviral compound entecavir.
DST2105
A long-acting artificial tear treatment for dry eye, utilizing Silica Matrix technology to provide relief throughout the day with a single drop.
Long-Acting Injectables
Development of long-acting injectable depots for various therapeutic areas, using Silica Matrix technology to provide sustained drug release.
Ocular Drug Delivery
Silica Matrix-based formulation platforms for ophthalmic drug delivery, designed to enable long-lasting drug effects and reduce the need for repeated intravitreal injections.
Supergeneric/505(b)(2) Drug Development
Development of supergeneric drug products by combining silica-based drug delivery technology with known active substances to create products with superior characteristics over the original brand.
DelSiTech Silica Matrix
A biodegradable silica-based drug delivery technology for controlled release of small molecules, biopharmaceuticals, and viral vectors.
DST1308
An injectable subcutaneous depot product for chronic hepatitis B, designed to improve patient adherence by providing a three-month release of the antiviral compound entecavir.
DST2105
A long-acting artificial tear treatment for dry eye, utilizing Silica Matrix technology to provide relief throughout the day with a single drop.
Long-Acting Injectables
Development of long-acting injectable depots for various therapeutic areas, using Silica Matrix technology to provide sustained drug release.
Ocular Drug Delivery
Silica Matrix-based formulation platforms for ophthalmic drug delivery, designed to enable long-lasting drug effects and reduce the need for repeated intravitreal injections.
Supergeneric/505(b)(2) Drug Development
Development of supergeneric drug products by combining silica-based drug delivery technology with known active substances to create products with superior characteristics over the original brand.
Services
Licensing and collaborative development agreements to apply controlled-release matrices to third-party compounds for development and commercialization in human and animal health.
Project-based collaborations to formulate candidate compounds into long-acting controlled-release injectables or implants, including preclinical release characterization and translation support.
Participation in multi-partner, publicly funded research projects to develop material libraries and delivery technologies through consortium research.
In-house non-GLP analytical testing services to support discovery and early development projects, intended to reduce project timelines and cost compared with outsourced GLP/GMP testing.
Licensing and collaborative development agreements to apply controlled-release matrices to third-party compounds for development and commercialization in human and animal health.
Project-based collaborations to formulate candidate compounds into long-acting controlled-release injectables or implants, including preclinical release characterization and translation support.
Participation in multi-partner, publicly funded research projects to develop material libraries and delivery technologies through consortium research.
In-house non-GLP analytical testing services to support discovery and early development projects, intended to reduce project timelines and cost compared with outsourced GLP/GMP testing.
Expertise Areas
- Controlled-release formulation development
- Silica-based biomaterials for drug delivery
- Vaccine and viral-vector thermostabilization
- Ophthalmic sustained-release delivery
Key Technologies
- Biodegradable silica-based matrices
- Inorganic nanomatrix synthesis
- Silica hydrogel composite formulations
- Thermostabilization techniques for viral vaccines and vectors
News & Updates
DelSiTech participated in the CRS Annual Meeting & Exposition in Philadelphia, showcasing its latest drug delivery solutions.
DelSiTech attended the BIO International Convention in Boston, engaging with industry partners and presenting its technology.
DelSiTech presented its vaccine delivery technology at the World Vaccine Congress in Washington.
DelSiTech was granted significant research funding by the EU Horizon 2020 program to develop nanomatrices for targeted drug therapies, including treatments for bone healing and skin wounds.
An article in Pharma Tech Focus highlighted the potential of DelSiTech’s silica matrix technology to enable room temperature storage of vaccines and medicines.
A 4-page company insight article and advertisement about DelSiTech’s silica matrix technology were published in Pharma Technology Focus magazine.
DelSiTech participated in the CRS Annual Meeting & Exposition in Philadelphia, showcasing its latest drug delivery solutions.
DelSiTech attended the BIO International Convention in Boston, engaging with industry partners and presenting its technology.
DelSiTech presented its vaccine delivery technology at the World Vaccine Congress in Washington.
DelSiTech was granted significant research funding by the EU Horizon 2020 program to develop nanomatrices for targeted drug therapies, including treatments for bone healing and skin wounds.
An article in Pharma Tech Focus highlighted the potential of DelSiTech’s silica matrix technology to enable room temperature storage of vaccines and medicines.
A 4-page company insight article and advertisement about DelSiTech’s silica matrix technology were published in Pharma Technology Focus magazine.